Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

NEXT STORY
HOOKIPA Pharma to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
PREV STORY
SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Karyopharm Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress

author_avatar
NASDAQ Market News

Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

author_avatar
NASDAQ Market News

Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

author_avatar
NASDAQ Market News